Who makes TSC-202-A0201?

TSC-202-A0201 is developed by TScan Therapeutics, Inc..

Last reviewed 2026-04-19 · How we verify

TSC-202-A0201

TScan Therapeutics, Inc. · Phase 1 active Biologic

At a glance

Generic name	TSC-202-A0201
Sponsor	TScan Therapeutics, Inc.
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

TSC-202-A0201 CI brief — competitive landscape report
TSC-202-A0201 updates RSS · CI watch RSS
TScan Therapeutics, Inc. portfolio CI